A study presented at a European Heart Rhythm Association meeting found that patients who received Boston Scientific's subcutaneous implantable cardiac defibrillator saw fewer major complications than those treated with conventional transvenous ICDs. The S-ICD device, which uses electrodes inserted below the skin instead of cardiac leads, already has U.S. and European approval.

Related Summaries